Patients with positive MGMT promoter methylation status shows higher tumor mutation burden values (P = 0.050; Fig. 1K); however, no differences in tumor mutation burden distribution were observed among patients with early-onset and late-onset GBM categorized by these factors (MGMT promoter methylation, chromosome 7 gain and 10 loss, KIT amplifications, and TERT mutation) (Fig. S2A–D). This evidence concerns the gene MGMT and glioblastoma.